The Akkermansia Company

What The Akkermansia Company does

The Akkermansia Company (TAC) is a Belgium-based microbiome nutrition company that develops and commercializes dietary supplements built around its proprietary pasteurized Akkermansia muciniphila MucT strain — a postbiotic form of a commensal gut bacterium originally isolated in 2004 at Wageningen University. The company was co-founded by the strain's scientific discoverers, Prof. Willem M. de Vos (Chief Technology Officer) and Prof. Patrice D. Cani, and holds broad patents covering the Akkermansia species and the pasteurized MucT variant. Akkermansia muciniphila MucT is the only form of the bacterium approved by the European Food Safety Authority (EFSA) for use as a dietary supplement and in foods in Europe, providing a regulatory and IP-backed moat.

The product portfolio consists of two formulations sold in consumer and healthcare professional variants: Akkermansia Essential (30 Billion CFU pasteurized MucT) for gut barrier integrity, weight maintenance, and insulin function; and Healthy Weight with Glucose Control, which combines MucT with chromium, EGCG green tea extract, vitamin B2, and vitamin D3 for targeted metabolic support. The company generates revenue through a subscription-based direct-to-consumer e-commerce channel (Shopify storefront, $44.85-$65/month per subscriber) and a parallel healthcare professional channel distributing professional-grade case packs (12 one-month packs) via the Fullscript platform. In June 2025, TAC was acquired by Danone, integrating the MucT strain and brand into Danone's gut health and next-generation biotic strategy.

Name

The Akkermansia Company

Legal name

The Akkermansia Company

Website

https://theakkermansiacompany.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

The Akkermansia Company is a Belgium-based microbiome nutrition company that commercializes EFSA-approved pasteurized Akkermansia muciniphila MucT dietary supplements for gut barrier, weight management, and metabolic health via D2C subscriptions and a healthcare professional channel, acquired by Danone in June 2025.

Ownership category

akta.pro rank

Product category

Dietary Supplements

NAICS

Food (Health) Supplement Retailers (456191)

SIC

Food And Kindred Products (2000)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

Keywords

• Postbiotic supplements
• Gut health supplements
• Akkermansia muciniphila
• Metabolic health products
• Weight management supplements

Headquarters

HQ city

Mont-saint-guibert

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Technology or R&D, Personnel

Revenue model

1. Direct Consumer Supplement Sales: The company generates revenue through direct-to-consumer sales of two main dietary supplement products: Akkermansia Essential and Healthy Weight with Glucose Control. Products are sold through e-commerce subscriptions with monthly or quarterly billing options.
2. Healthcare Professional Sales: Sales to healthcare practitioners through professional accounts and the Fullscript platform, with products sold in case quantities (12 one-month packs) at professional pricing.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Core offering

The Akkermansia Company develops and sells dietary supplements based on its proprietary pasteurized Akkermansia muciniphila MucT strain, a next-generation postbiotic targeting gut barrier integrity, weight management, and metabolic health. Its product portfolio includes Akkermansia Essential (core MucT formulation) and Healthy Weight with Glucose Control (MucT combined with chromium, EGCG green tea extract, and vitamins B2 and D3), each available in consumer and healthcare professional versions.

Product overview

The Akkermansia Company offers a focused portfolio of dietary supplements centered around its proprietary pasteurized Akkermansia muciniphila MucT strain—a clinically studied postbiotic for gut barrier integrity and metabolic health. The product line consists of four offerings: Akkermansia Essential (consumer and professional versions) providing the core 30 Billion CFU MucT formulation for general gut health, weight maintenance, and insulin function; and Healthy Weight with Glucose Control (consumer and professional versions) combining MucT with additional ingredients (chromium, EGCG green tea, vitamins B2 and D3) for targeted weight management and metabolic support. Both products are available in consumer retail and healthcare professional formulations, with the professional versions sold in bulk cases.

Differentiator

Problem solved

Functional benefit

Products and services

• Akkermansia Essential (Consumer) Dietary supplement containing 30 Billion CFU of pasteurized Akkermansia muciniphila MucT for weight maintenance, gut barrier protection, insulin function, immune function, and antioxidant defense. Sold direct-to-consumer through the company's Shopify website with monthly or quarterly subscription options.
• Akkermansia Essential (Professional) Healthcare practitioner-specific version of Akkermansia Essential supplement sold as a case of 12 one-month packs containing the same pasteurized Akkermansia muciniphila MucT formulation. Distributed to licensed healthcare providers through the Fullscript platform at professional pricing.
• Healthy Weight with Glucose Control (Consumer) Dietary supplement combining pasteurized Akkermansia muciniphila MucT with chromium, EGCG green tea extract, vitamin B2, and vitamin D3 to support weight management, intestinal barrier function, healthy inflammatory response, and glucose metabolism. Sold direct-to-consumer via subscription.
• Healthy Weight with Glucose Control (Professional) Healthcare practitioner-specific version of Healthy Weight with Glucose Control supplement with the same formulation of Akkermansia muciniphila MucT, chromium, EGCG, and vitamins. Sold in bulk to licensed healthcare providers through professional accounts and the Fullscript catalog.

Quantifiable outcome

• Weight regain reduced to 1.2kg vs 3.2kg placebo during maintenance phase (P=0.012)
• +6 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of CopenhagencoreStrategic or Co-development Partner · 1 May 2026Academic research partner in the clinical trial published in Nature Medicine (May 2026) on pasteurized Akkermansia muciniphila MucT for weight loss maintenance.
• Wageningen University & ResearchcoreStrategic or Co-development Partner · 1 May 2026Academic partner where co-founder Prof. Willem M. de Vos served as Chair of Microbiology for over 25 years. Partner in clinical research on Akkermansia muciniphila MucT.
• Maastricht University Medical Center+coreStrategic or Co-development Partner · 1 June 2025Academic research partner that conducted the randomized controlled trial published in Nature Medicine demonstrating MucT's effectiveness for weight loss maintenance. Part of the consortium with University of Copenhagen and Wageningen University.
• FullscriptminorChannel Partner/ Reseller/ DistributorHealthcare professional distribution platform through which The Akkermansia Company sells professional-grade products to licensed healthcare practitioners.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Viome: Viome pairs gut microbiome testing with personalized nutrition recommendations and supplements. It overlaps with The Akkermansia Company on gut health diagnostics-adjacent wellness, premium DTC positioning, and subscription revenue.
• Ritual: Ritual is a premium DTC supplement brand with a subscription model, science-forward branding, and clinically-backed formulations. It competes for the same health-conscious, educated supplement consumer with similar messaging architecture.
• Athletic Greens (AG1): AG1 is a premium DTC daily nutritional supplement sold via subscription at a comparable price point to Akkermansia Essential. It competes for the same health-conscious consumer wallet share with gut-health-adjacent claims.
• Seed Health: Seed is a premium DTC microbiome brand selling scientifically-formulated probiotic and prebiotic subscriptions. It targets similar gut health and metabolic wellness consumers with subscription-based pricing and clinical positioning.
• Care/of: Care/of is a personalized DTC vitamin and supplement subscription brand competing for the same premium, wellness-oriented consumer segment with a subscription e-commerce model.
• Pendulum Therapeutics: Pendulum is the most direct competitor — it sells a probiotic containing a live Akkermansia muciniphila strain (and other strains) targeting metabolic health and glucose control, overlapping directly with The Akkermansia Company's MucT-based formulations.

Broad incumbents

• Culturelle: Culturelle is one of the largest mass-market probiotic brands (Lactobacillus rhamnosus GG). It is a broad incumbent in the digestive health category where The Akkermansia Company competes, with substantially broader retail distribution.
• Yakult: Yakult is a globally established probiotic functional-food brand (Lactobacillus casei strain Shirota). It competes in the broader gut health category via retail distribution and is a potential benchmark for the functional-food expansion path of Akkermansia MucT.

Others

• Novonesis (formerly Novozymes / Chr. Hansen): Novonesis is a global B2B supplier of probiotic, enzyme, and postbiotic ingredients used by supplement and food manufacturers. It is relevant as an enabling supplier in the microbiome value chain that The Akkermansia Company ultimately depends on for downstream scale.

Emerging players

• BIOHM Health: BIOHM develops microbiome-focused supplements addressing gut and oral mycobiome, positioned at the intersection of probiotics and functional nutrition — comparable to The Akkermansia Company's gut barrier and metabolic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/theakkermansiacompany
• Instagraminstagram.com/theakkermansiaco
• Xx.com/theakkermansiac
• LinkedInlinkedin.com/company/the-akkermansia-company-belgium

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Akkermansia Company